Загрузка...
Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
One of the most feared repercussions of type 2 diabetes mellitus is the risk of adverse cardiovascular outcomes. The current antidiabetic agents on the market have had difficulty in showing cardiovascular outcome improvement. The EMPA-REG OUTCOME trial studied the sodium-glucose cotransporter 2 inhi...
Сохранить в:
| Опубликовано в: : | Ther Clin Risk Manag |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5422533/ https://ncbi.nlm.nih.gov/pubmed/28496330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S97619 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|